Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase

References

1. Drlica K., Franco R. J. Inhibitors of DNA topoisomerases. Biochemistry 1988; 27:2254–2259
   [Google Scholar]
2. Lewin C. S., Allen R. A., Amyes S. G. B. Potential mechanisms of resistance to the modem fluorinated 4-quinolones. J Med Microbiol 1990; 31:153–161
   [Google Scholar]
3. Shen L. L., Mitscher L. A. Sharma PN et al., Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug-DNA binding model. Biochemistry 1989; 28:3886–3894
   [Google Scholar]
4. Dietz W. H., Cook T. M., Goss W. A. Mechanism of action of nalidixic acid on Escherichia coli: III. Conditions required for lethality. J Bacterial 1966; 91:768–773
   [Google Scholar]
5. Smith J. T. Awakening the slumbering potential of the 4-quinolone antibacterials. Pharm J 1984; 233:299–305
   [Google Scholar]
6. Smith J. T., Lewin C. S. Chemistry and mechanisms of action of the quinolone antibacterials. In Andriole V. T. (ed) The quinolones London: Academic Press; 198823–82
   [Google Scholar]
7. Lewin C. S., Amyes S. G. B. The bactericidal activity of DR-3355, an optically active isomer of ofloxacin. J Med Microbiol 1989; 30:227–231
   [Google Scholar]
8. Lewin C. S., Amyes S. G. B. Conditions required for the bactericidal activity of fleroxacin and pefloxacin against Escherichia coli KL16. J Med Microbiol 1990; 32:83–86
   [Google Scholar]
9. Lewin C. S., Amyes S. G. B., Smith J. T. Bactericidal activity of enoxacin and lomefloxacin against Escherichia coli KL16. Eur.J.Clin Microbiol Infect Dis 1989; 8:731–733
   [Google Scholar]
10. Dalhoff A. Interaction of aminoglycosides and ciprofloxacin with bacterial membranes. In Adam H, Hahn W., Opferkuch W. (eds) The influence of antibiotics on the host-parasite relationship II. Springer-Verlag Berlin and Heidelberg: 198516–27
    [Google Scholar]
11. Hane M. W., Wood T. H. Escherichia coli K-12 mutants resistant to nalidixic acid: genetic mapping and dominance studies. J.Bacteriol 1969; 99:238–241
    [Google Scholar]
12. Yamagishi J., Yoshida H., Yamayoshi M, Nakamura S. Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet 1986; 204:367–373
    [Google Scholar]
13. Hrebenda J., Heleszko H., Brzostek K., Bielecki J. Mutation affecting resistance of Escherichia coli K12 to nalidixic acid. J Gen Microbiol 1985; 131:2285–2292
    [Google Scholar]
14. Lewin C. S., Howard B. M. A., Ratcliffe N. T., Smith J. T. 4-quinolones and the SOS response. J Med Microbiol 1989; 29:139–144
    [Google Scholar]
15. Lewin C. S., Smith J. T. Bactericidal mechanisms of ofloxacin. J Antimicrob Chemother 1988; 22: Suppl C 1–8
    [Google Scholar]
16. Smith J. T. Frequency and expression of mutational resistance to the 4-quinolone antibacterials. Scand J Infect Dis 1986; 49: Suppl 115–123
    [Google Scholar]
17. Barry A. L., Gardiner R. V. Packer R-R. Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid. Diagn Microbiol Infect Dis 1987; 6:77–79
    [Google Scholar]
18. Fernandes P. B., Hanson C. W., Stamm J. M., Votjko C., Shipkowitz N. L. St Martin E. The frequency of in-vitro resistance development to fluoroquinolones and the use of a murine pyelonephritis model to demonstrate selection of resistance in vivo. J Antimicrob Chemother 1987; 19:449–465
    [Google Scholar]
19. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother 1985; 28:581–586
    [Google Scholar]
20. Lewin C. S., Smith J. T. Conditions required for the bactericidal activity of the 4-quinolones against Serratia marcescens. J Med Microbiol (in press)
    [Google Scholar]
21. Watanabe M., Inoue M., Mitsuhashi S. In vitro activity of amifloxacin against outer membrane mutants of the family enterobacteriaceae and frequency of spontaneous resistance. Antimicrob Agents Chemother 1989; 33:1837–1840
    [Google Scholar]
22. Smith J. T. In-vitro and in-vivo mutation frequencies to resistance-do they correlate in the long term?. In Crumplin G. C. (ed) The 4-quinolone antibacterial agents in vitro Springer Verlag-Heidelberg 1990215–227
    [Google Scholar]
23. Lewin C. S., Blakemore P., Drabu Y. J., Smith J. T. Loss of ciprofloxacin’s second killing action in Escherichia coli that have developed 4-quinolone resistance during therapy. J Antimicrob Chemother (in press)
    [Google Scholar]